PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.

被引：3
|
作者：
Ray-Coquard, Isabelle Laure
Harter, Philipp
Martin, Antonio Gonzalez
Cropet, Claire
Pignata, Sandro
Fujiwara, Keiichi
Marth, Christian
Vergote, Ignace
Mirza, Mansoor Raza
Colombo, Nicoletta
Rosenberg, Per
Maenpaa, Johanna Unelma
lauraine, Eric PujaDe
机构：
[1] GINECO Grp, Lyon, France
[2] Ctr Leon Berard, Lyon, France
[3] AGO Germany, Essen, Germany
[4] GEICO, Madrid, Spain
[5] MD Anderson Canc Ctr Madrid, Madrid, Spain
[6] GINECO, Lyon, France
[7] MITO, Naples, Italy
[8] GOTIC, Hidaka, Japan
[9] AGO Austria, Innsbruck, Austria
[10] Univ Hosp Leuven, BGOG, Leuven, Belgium
[11] Copenhagen Univ Hosp, NSGO, Copenhagen, Denmark
[12] MANGO, Milan, Italy
[13] NSGO, Linkoping, Sweden
[14] Univ Hosp, Linkoping, Sweden
[15] NSGO, Tampere, Finland
[16] GINECO, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS5605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5605
引用
收藏
页数：3
相关论文
共 50 条
  • [1] PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.
    Ray-Coquard, Isabelle
    Selle, Frederic
    Harter, Philipp
    Cropet, Claire
    Marth, Christian
    Vergote, Ignace
    Fujiwara, Keiichi
    Gonzalez-Martin, Antonio
    Pignata, Sandro
    Colombo, Nicoletta
    Maenpaa, Johanna Unelma
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] PHASE III PAOLA-1/ENGOT-OV25 TRIAL: OLAPARIB PLUS BEVACIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH NEWLY DIAGNOSED, ADVANCED OVARIAN CANCER TREATED WITH PLATINUM-BASED CHEMOTHERAPY PLUS BEVACIZUMAB
    Harter, P.
    Mouret-Reynier, M. A.
    Pignata, S.
    Cropet, C.
    Gonzalez-Martin, A.
    Bogner, G.
    Fujiwara, K.
    Vergote, I.
    Colombo, N.
    Maenpaa, J.
    Floquet, A.
    El-Balat, A.
    Lorusso, D.
    Guerra Alia, E. M.
    Fabbro, M.
    Schmalfeldt, B.
    Blessard, A. C. Hardy
    Runnebaum, I.
    Pujade-Lauraine, E.
    Ray-Coquard, I.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A10 - A11
  • [3] Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab
    Harter, Philipp
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (04) : 451 - 452
  • [4] SAFETY AND QUALITY OF LIFE OF FIRST-LINE MAINTENANCE OLAPARIB PLUS BEVACIZUMAB IN OLDER PATIENTS WITH ADVANCED OVARIAN CANCER IN THE PAOLA-1 TRIAL
    Montegut, C.
    Falandry, C.
    Cinieri, S.
    Montane, L.
    Rousseau, F.
    Joly, F.
    Frindte, J.
    Mosconi, A. M.
    Guerra-Alia, E.
    Schauer, C.
    Fujiwara, H.
    Vergote, I. B.
    Parma, G.
    Lindahl, G.
    Anota, A.
    Canzler, U.
    Marme, F.
    Pujade-Lauraine, E.
    Ray-Coquard, I.
    Sabatier, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A201 - A202
  • [5] COST-EFFECTIVENESS OF OLAPARIB PLUS BEVACIZUMAB FIRST-LINE MAINTENANCE IN OVARIAN CANCER ALONGSIDE THE PAOLA-1 TRIAL
    Perrier, L.
    Zarca, K.
    Cadet, T.
    Morelle, M.
    Cropet, C.
    Burges, A.
    Cecere, S. C.
    Palacio, I
    Polterauer, S.
    Yoshida, H.
    Vuylsteke, P.
    Colombo, N.
    Nottrup, T. J.
    Abdeddaim, C.
    El-Balat, A.
    Cinieri, S.
    Herrero, A.
    Kaminski, M. C.
    Pujade-Lauraine, E.
    Durand-Zaleski, I
    Ray-Coquard, I
    VALUE IN HEALTH, 2023, 26 (12) : S61 - S62
  • [6] Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab ( bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
    Schnelzer, A.
    Harter, P.
    Sehouli, J.
    Canzler, U.
    Marme, F.
    De Gregorio, N.
    Buderath, P.
    Lueck, H. J.
    Gropp-Meier, M.
    Runnebaum, I
    Belau, A.
    Renner, S.
    Schmalfeldt, B.
    El-Balat, A.
    Burges, A.
    Hillemanns, P.
    Denschlag, D.
    Bauerschlag, D.
    Hanker, L.
    Ray-Coquard, I
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (10) : E87 - E87
  • [7] Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev
    de Gregorio, Nikolaus
    Harter, Philipp
    Sehouli, Lalid
    Canzler, Ulrich
    Marme, Frederik
    Buderath, Paul
    Lueck, Hans-Joachim
    Gropp-Meier, Martina
    Runnebaum, Ingo B.
    Belau, Antje
    Renner, Stefan
    Schmalfeldt, Barbara
    El-Balat, Ahmed
    Burges, Alexander
    Hillemanns, Peter
    Denschlag, Dominik
    Bauerschlag, Dirk
    Hanker, Lars
    Schnelzer, Andreas
    Ray-Coquard, Isabelle
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 93 - 93
  • [8] Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
    Ray-Coquard, I. L.
    Pautier, P.
    Pignata, S.
    Perol, D.
    Gonzalez-Martin, A.
    Sevelda, P.
    Fujiwara, K.
    Vergote, I. B.
    Colombo, N.
    Maenpaa, J.
    Selle, F.
    Sehouli, J.
    Lorusso, D.
    Alia, E. M. Guerra
    Lefeuvre-Plesse, C.
    Canzler, U.
    Lortholary, A.
    Marme, F.
    Pujade-Lauraine, E.
    Harter, P.
    ANNALS OF ONCOLOGY, 2019, 30 : 894 - +
  • [9] Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
    Ray-Coquard, I.
    Leary, A.
    Pignata, S.
    Cropet, C.
    Gonzalez-Martin, A.
    Marth, C.
    Nagao, S.
    Vergote, I.
    Colombo, N.
    Maenpaa, J.
    Selle, F.
    Sehouli, J.
    Lorusso, D.
    Alia, E. M. Guerra
    Bogner, G.
    Yoshida, H.
    Lefeuvre-Plesse, C.
    Buderath, P.
    Mosconi, A. M.
    Lortholary, A.
    Burges, A.
    Medioni, J.
    El-Balat, A.
    Rodrigues, M.
    Park-Simon, T. -W.
    Dubot, C.
    Denschlag, D.
    You, B.
    Pujade-Lauraine, E.
    Harter, P.
    ANNALS OF ONCOLOGY, 2023, 34 (08) : 681 - 692
  • [10] Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
    Fujiwara, K.
    Harter, P.
    Leary, A.
    Perol, D.
    Pignata, S.
    Gonzalez-Martin, A.
    Petru, E.
    van Nieuwenhuysen, E.
    Colombo, N.
    Maenpaa, J.
    Selle, F.
    de Gregorio, N.
    Lorusso, D.
    Alia, E. M. Guerra
    Lefeuvre-Plesse, C.
    Buderath, P.
    Lortholary, A.
    Burges, A.
    Pujade-Lauraine, E.
    Ray-Coquard, I. L.
    ANNALS OF ONCOLOGY, 2019, 30
12345